Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

February 15, 2023

London Stock Exchange GB Health Care Biotechnology earnings 23 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and welcome to the conference call covering Palatin's operating results for the second quarter of fiscal year 2023. For now, everyone has been placed in listen-only mode. After the formal presentation, there will be a question and answer session. Should you need help from an operator at any point during this conference, press star zero on your telephone keypad. Please be aware that this conference is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate, and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now I would like to turn the call over to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.

Carl Spana

executive
#2

Thanks. Morning, everyone, and glad to have you with us for Palatin's call covering the second quarter of fiscal 2023. This is Dr. Carl Spana speaking — I serve as CEO and President of Palatin. Joining me today is Steve Wills, who holds the roles of Executive Vice President, Chief Financial Officer, and Chief Operating Officer at Palatin. At this point I'll hand things over to Steve, and he'll provide the update on finances and operations. Steve.

Steve Wills

executive
#3

Thanks, Carl. Good morning, everybody. Carl is going to give you details on our development programs a little later. I'll begin with Vyleesi, our commercial product that's approved for hypoactive sexual desire disorder in premenopausal women. The aim of the Vyleesi program is to show commercial product value in the marketplace, and we are doing that, with the objective of re-licensing the U.S. rights to a committed women's healthcare company. For the fiscal second quarter that ended December 31st, 2022, gross product sales came to 2.6 million, up 14% from the prior quarter and up 238% from the comparable quarter last year. Net product revenue of 1 million rose 18% versus the prior quarter and rose 1,323% versus the comparable quarter last year. We are pleased, in fact very pleased, that net product revenue for the quarter exceeded Vyleesi operating expenses. Total prescriptions dispensed were up 12% from the prior quarter and up 134% from the comparable quarter last year. Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed all rose over both the prior quarter and the comparable quarter last year. Turning to our recent registered direct offering on October 31, 2022, Palatin entered into a securities purchase agreement with an institutional investor, selling and issuing an aggregate of approximately 1 million shares of Palatin common stock, pre-funded warrants to purchase approximately 0.8 million shares of Palatin common stock, and common warrants to purchase up to approximately 1.8 million shares of Palatin common stock.

Steve Wills

executive
#4

Every share of common stock and pre-funded warrant came with one common warrant attached, at a combined offering price of roughly $5.50. Those common warrants carry an exercise price of $5.83 per share and expire five and one half years after issuance. The offering closed on November 2, 2022, and Palatin took in gross proceeds of $10 million. After December 31, 2022, the institutional investor exercised every outstanding pre-funded warrant, covering about 0.8 million shares of Palatin's common stock. Moving to the next item. Palatin took part in the State of New Jersey's Technology Business Tax Certificate Transfer Program. Through this program, approved biotech companies holding unused net operating losses, or NOLs, along with unused research and development credits, can sell those tax benefits to unaffiliated, profitable corporate taxpayers within the State of New Jersey. In December 2022, Palatin secured final approval to sell the NOLs and R&D credits. That brought in approximately 4.7 million in January 2023. As a result, Palatin recorded the income tax benefit for the three and six months ended December 31, 2022, along with a corresponding receivable as of December 31, 2022. To repeat, all of the funds arrived in early January 2023. Now, on to specific financial results for the second quarter ended December 31, 2022.

Steve Wills

executive
#5

Turning to revenue. Our total revenue is made up of gross product sales for Vyleesi, net of allowances and accruals, plus license and contract revenue. As I mentioned earlier, Vyleesi gross product sales came in at 2.6 million, with net product revenue of 1,026,000, versus gross product sales of 0.8 million and net product revenue of 72,000 in the same quarter a year ago. That represents a 238% rise in gross product sales and a 1,323% rise in net product revenue over the comparable quarter last year. During the quarter that ended December 31, 2021, Palatin recorded 250,000 in license and contract revenue under our license agreement with Fosun Pharma. On operating expenses, total operating expenses were 6.6 million, compared with 8.8 million in the comparable quarter last year. That decline was primarily driven by reduced spending on our development programs and by the gain we recognized from amending certain minimum purchase commitments with third-party vendors. Net loss. Palatin posted a net loss of 1.4 million, or 0.13 per basic and diluted common share, versus a net loss of 8.7 million, or 0.91 per basic and diluted common share, in the comparable period last year. The smaller net loss relative to the comparable quarter last year was mainly attributable to recognition of the income tax benefit I mentioned earlier of 4.7 million — again, that's the sale of New Jersey NOLs — along with a reduction in operating expenses of roughly 2.2 million and higher net product revenue from Vyleesi.

Steve Wills

executive
#6

Let's look at cash. Palatin's cash and cash equivalents stood at roughly 21.2 million as of December 31st, 2022, along with 6.5 million in accounts and other receivables. That compares with cash and cash equivalents of 21.2 million and 2 million of accounts receivable as of September 30th, 2022, and 29.9 million with 1.8 million of accounts receivable as of June 30th, 2022. Under our current operating plan, we believe existing cash and cash equivalents and receivables will be enough to fund currently anticipated operating expenses through calendar year 2023. With that, I'll hand the call back to Carl.

Carl Spana

executive
#7

Thank you, Steve. As I've mentioned during earlier calls, our primary goals involve establishing the melanocortin system as a target for safe and effective medicines that treat inflammatory and autoimmune diseases, along with building a pipeline of innovative drugs. Two essential components go into achieving that objective. First, we need to deepen our knowledge of the way the melanocortin system operates by mapping the molecular mechanisms and key signaling pathways responsible for physiological effects. We do this via research conducted in Palatin's laboratory and through numerous collaborations with academic researchers. During calendar 2023, we have already had multiple abstracts accepted for presentation at scientific and medical meetings. Beyond that, we have manuscripts that have gone through peer review and been accepted for publication. These research efforts help us design better clinical trials and support our business development activities. The second component involves translating the science into clinical results and, ultimately, into therapeutics that address unmet medical needs. We are currently enrolling patients across three studies: MELODY-1, a phase three study in dry eye disease; a phase two study evaluating oral PL8177, a selective melanocortin-1 receptor agonist, in patients with ulcerative colitis; and the third, called BREAKOUT, a phase two study in diabetic patients with kidney disease.

Carl Spana

executive
#8

We expect data readouts from all 3 clinical studies during calendar 23. On top of that, each of those 3 studies is testing compounds whose mechanism involves modulating how the melanocortin system resolves pathological inflammation and supports tissue repair. To recap our second quarter fiscal 2023 results and look ahead to calendar 23. As Steve mentioned, Vyleesi keeps delivering impressive quarter-over-quarter growth across every key metric. We expect that growth to carry on. We're still making substantial headway in positioning the melanocortin system as an innovative therapeutic target for treating a range of inflammatory diseases. We're currently enrolling patients in 3 clinical studies that assess the efficacy and safety of our melanocortin target therapeutics. All 3 have data readouts planned in 2023. Our research work keeps deepening what we know about the melanocortin system, and the wider scientific, biotechnology, and pharmaceutical communities are taking notice. If things go well, those efforts will underpin further advancement of our innovative therapeutics and strengthen our push to draw partnerships with larger biotechnology and pharmaceutical companies that can help move our programs forward. Thank you for joining the Palatin second quarter fiscal 2023 conference call. More detail on our science and clinical programs is available on our website, www.palatin.com.

Carl Spana

executive
#9

More details about Vyleesi are available on the vyleesi.com site. Thanks to everyone. At this point, we'll take your questions.

Operator

operator
#10

We're moving into the question-and-answer portion now. Should you wish to pose a question, hit star one on your phone's keypad. A confirmation tone will signal that your line has joined the question queue. If you'd prefer to pull your question from the queue, press star two. Those of you on speaker equipment might need to lift your handset before tapping the star keys. Please stand by briefly while we poll for questions. Our first question comes from Joseph Pantginis of H.C. Wainwright & Co. Go ahead with your question. Your line is live.

Joe Pantginis

analyst
#11

Hey, guys. Good afternoon, or still good morning. Thanks for taking the question. A couple, if that's all right. Just zeroing in on Vyleesi for the moment. Steve, I was hoping you might give us some additional color on the refill rates you're currently seeing. Let's begin there.

Carl Spana

executive
#12

Okay, and thanks for that question, Joe. When it comes to how we handle the refill rate, there are two metrics to consider. The first is the share of TRx — that is, total prescriptions dispensed — that comes from refills. That figure has risen each month and certainly quarter-over-quarter. And that's not driven by TRx declining; in fact, it's even stronger than that, since our TRx is climbing by a larger amount. The second metric relates to the patient herself. To put it nicely, if just 10 women received a prescription or dispense, how many of them are coming back in line? That's also a very meaningful metric. We've watched that number climb every month and quarter-over-quarter as well, and we're now above 40% of any woman who has taken the first prescription or dispense having come back in line for a renewed script.

Joe Pantginis

analyst
#13

That's helpful and nice to hear. I suppose this is more of a scenario-type question. Obviously, you folks are really busy behind the scenes with the potential U.S. licensing of Vyleesi. So let me ask this scenario: apart from a U.S. licensee, what are you prepared to do with Vyleesi internally?

Steve Wills

executive
#14

So, as I said, the goal for Carl Spana, Steve, and the board is to locate a home for Vyleesi — in a good way — with a business that has a fairly substantial female healthcare franchise. That isn't our main focus as we move forward. We've made investments that we consider measured and informed. When we initially got the product back, we were actually losing significant money — multiple seven digits each quarter. Now, we had slightly better than break even for the quarter, which is great. What we're still focused on is demonstrating that these metrics can be extrapolated and that you can see it can be scaled up.

Carl Spana

executive
#15

With the right organization and the right people handling it, this product could achieve far more than it currently does under us. We're better positioned now for those conversations. We won't be hasty about any of it. Vyleesi, we believe, carries meaningful value, and it isn't costing us anything, so to speak. Carl says he's fine if I end up putting in extra nights and weekends — I'm on a fixed salary, so that works. Interest on our side is definitely there, and we do think that eventually, at the right moment, we'll be passing the baton to a new partner. That covers the U.S. side.

Joe Pantginis

analyst
#16

Understood. So, regarding geography, I suppose we haven't had much visibility there, and I hope you can share whatever expectations you have coming from your existing ex-U.S. licensees in China as well as South Korea.

Carl Spana

executive
#17

Alright. Fosun is in the later stage of their phase three trial — let's just say a somewhat smaller, much smaller one — for regulatory approval. That ought to wrap up around mid-year, and after that they'll be submitting their filing for regulatory approval, if all goes according to plan. The first commercial sale — we don't expect that until, let's just say, mid-2024, maybe the second half of calendar 2024; I think that would be the best position they could be in. This, of course, is Kwangdong Pharmaceutical in South Korea. With Fosun, I think we're going to hold off a bit on some coming attractions. We're making solid progress with the Fosun partner. They're looking into several avenues to speed up revenue and regulatory approval. Carl and I would prefer to hold off on that until we have a bit more granularity, but they are 100% committed to moving the program forward and to commencing sales of Vyleesi in China as soon as possible.

Joe Pantginis

analyst
#18

Understood. That's really helpful. Many thanks.

Operator

operator
#19

Michael Higgins from Ladenburg Thalmann has the next question. Go ahead, your line is open — please ask.

Analyst

analyst
#20

Morning, everyone. Faizan Rajput here, speaking for Michael. We’ve got three questions, starting with the BREAKOUT trial. First: ClinicalTrials.gov right now lists 5 sites as re-recruiting — is that correct? And when should all seven sites be up and enrolling? Second: why isn’t there an arm with RAAS therapy by itself? Third: given that these patients undergo a renal biopsy after 12 months, when will you make the call on moving this program forward? Thanks.

Carl Spana

executive
#21

All right. Let's, let's — that's quite a mouthful. We'll go through them one by one. One reason we're running this study is that we're working closely with a nephrology group, a group of nephrologists who have a large patient base. We honestly believe enrollment in this study will be essentially complete, likely by the end — by the middle, by the middle to the end of the second quarter. Five sites are up at this point. The remaining seven ought to come on board fairly fast. Enrollment is actually going quite smoothly in that study, and dosing of patients has already begun. My expectation is that this study moves very, very fast given the group we're partnering with. They're highly motivated. In fact, they've been seeking a melanocortin-based therapeutic to evaluate in kidney patients — diabetic patients with kidney disease. The other question is why there's no straight control arm. That really stems from how this was designed. For one thing, these patients don't spontaneously revert. This isn't a kind of inflammatory condition or immune condition where these patients — or rather, it isn't actually an immune condition, it's more inflammatory — where these patients wax and wane.

Carl Spana

executive
#22

They’re going to keep making steady progress. That’s one factor. The second factor is that this study was truly set up as an initial look to really learn, you know, just how effective a melanocortin can actually be in this patient population. That’s genuinely, genuinely the rationale behind it. And cost is another consideration, because with this, you know, we’ll be able to enroll 40 patients fairly quickly. We’ll get a very solid read at the 6-month time point, and then we’ll decide how to proceed from there. Then, I’m losing track of what your third point was.

Analyst

analyst
#23

And then the third item was about timing for moving the program forward, since these patients undergo a renal biopsy at the 12-month mark, correct?

Carl Spana

executive
#24

Since this is an open-label study, data will of course keep coming in. As each patient’s data arrives, we’ll see it, and from there we’ll obviously take a look. Once the data come in, we have to make some decisions, and then be ready to move forward. Even after the last patient out, there are still 6 months more before you get that patient’s final data — I think we’ll know whether the study works, and we’ll be able to make some decisions during that intervening period. Frankly, in today’s world, turning around clinical trial times and getting clinical trial sites, materials, and so on will take longer than the period from the last patient leaving until that patient’s last data point comes in.

Analyst

analyst
#25

Alright, excellent. Thanks. I'll rejoin the queue.

Operator

operator
#26

Moving on, our next question comes from John Newman at Canaccord. Go ahead and ask your question — your line is open.

John Newman

analyst
#27

Hey everyone, thanks for taking my question. It's really just about the regulatory filing strategy for the dry eye indication. If you could remind us, what do you figure you'll need in terms of how many clinical studies, and then also your thinking around the endpoint that you plan to take forward to the agency there. Thanks.

Carl Spana

executive
#28

John, thank you. So in dry eye disease, clearly there are a number of strategies you could use. The most efficient one, of course, would be having 2 clinical trials — Phase 3 clinical trials — that replicate, with both a sign and a symptom reaching significance, statistical significance, in both studies. Obviously, the same sign and the same symptom in both studies. Beyond that, you'd need your open-label safety, you know. Depending on how you do it, that's technically 3 studies. That's really what we're aiming for here, right? That's the most efficient approach. That's among the reasons we built an interim assessment into the first study. It's really to make sure we can take a look, confirm we were on track, confirm we have the right signs and the right symptoms as we move forward — you know, have a successful first Phase 3 trial, which is where we get a sign and a symptom, and then that would need to replicate in a 2nd study. If someone were to hit only, say, for example, a sign, and had a very good idea of how you might get to the symptom, or vice versa, then you could pursue an alternative strategy, which would be doing 4 Phase 3 studies.

Carl Spana

executive
#29

They might be smaller in size, naturally, where you'd be looking to, you know, hit the sign at two and then the symptom at the 2nd. That's obviously a longer quarter-term strategy, and a more expensive one. What we're really aiming for overall is to nail the sign and the symptom in both, you know, MELODY-1 and then the follow-on MELODY-2 — MELODY-3 would be an open label safety study. That would be the most cost-effective and efficient path forward. As for signs and symptoms, some are predefined, but of course, based on the interim assessment, we do have some flexibility there. I think I'd rather wait until the second quarter to give a bit more detail on that. We have an abstract on the first 120 patients that's been accepted for presentation, and I don't wanna front-run that. There'll be some nice coming attractions in late April at the ARVO meeting — that's a meeting on vision and research in ophthalmology, happening as I said in, I think, April down in New Orleans. We have a nice presentation there on those first 120 patients, and we'll get a lot more clarity on how we expect the first phase 3 study to read out.

John Newman

analyst
#30

Alright, that's great — thanks a lot.

Operator

operator
#31

That brings our Q&A portion to a close. At this point, I'll hand things back to Carl Spana so he can offer any closing comments.

Carl Spana

executive
#32

Thank you. Steve and I want to express our appreciation to everyone for joining the Palatin second quarter fiscal 2023 conference call. As you can tell, we are really moving quickly here. Vyleesi is performing well with Steve at the helm. On the research and development side, we currently have three clinical trials actively enrolling patients. There are plenty of data readouts coming this year. This is a major year for us. Steve and I feel very enthusiastic about what we will be delivering. Keep watching. Much is on the way. Once again, Steve and I appreciate all of you. Have a wonderful day, and we look forward to bringing you an update next quarter. Thank you.

Operator

operator
#33

That brings today's conference to a close, and you're free to drop off your lines now. Thanks for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.